AENZ yields 103.09% · MRK yields 2.76%● Live data
📍 AENZ pulled ahead of the other in Year 1
Combined, AENZ + MRK cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AENZ + MRK for your $10,000?
Aenza S.A.A., together with its subsidiaries, engages in the Infrastructure, Energy, Engineering and Construction, and Real Estate management businesses in Peru, Bolivia, Chile, Mexico, and Colombia. The company's Infrastructure segment offers long-term concessions or similar contractual arrangements in Peru for three toll roads, the Lima Metro, a wastewater treatment plant in Lima, four producing oil fields, five multiple fuel storage facilities, and a gas processing plant, as well as operation and maintenance services for infrastructure assets. Its Engineering and Construction segment provides traditional engineering services, such as structural, civil, and design engineering; and services ranging from architectural planning to advanced specialties comprising process design, simulation, and environmental services. This segment also provides services related to civil works, which include construction of hydroelectric power stations and other large infrastructure facilities; electro mechanic construction, such as concentrator plants, oil, and natural gas pipelines, and transmission lines; and building construction comprising office and residential buildings, hotels, affordable housing projects, shopping centers, and industrial facilities, as well as procurement services; maintains plants and industrial facilities; and rents construction equipment. It serves mining, power, oil and gas, transportation, real estate, and other infrastructure sectors. The company's Real Estate segment develops and sells homes, and office and commercial spaces. The company was formerly known as Graña y Montero S.A.A. and changed its name to Aenza S.A.A. in November 2020. Aenza S.A.A. was founded in 1933 and is based in Surquillo, Peru.
Full AENZ Calculator →Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Full MRK Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.